Search the Newsreel

Insider Selling: Glaukos (NYSE:GKOS) COO Sells 60,000 Shares of Stock

Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for approximately $10.8 million, reducing his direct ownership by 45.25%. The sale occurred while Glaukos shares were trading near a 52-week high, and the company recently reported strong quarterly revenue and beat EPS …

Glaukos COO Joseph Gilliam sells $10.7m in stock

Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for $10.7 million after exercising stock options. These sales occurred when the stock was near its 52-week high, and Gilliam now beneficially owns 72,588 shares. The transactions follow recent strong Q2 2026 financial …

Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss

Glaukos (GKOS) shares rose 6.7% after the company increased its 2026 net sales guidance to US$680 million to US$700 million and narrowed its quarterly loss per share to US$0.31. This positive adjustment follows strong Q2 2026 sales of US$185.61 million and the introduction of …

Glaukos Corp stock hits all-time high at 184.45 USD

Glaukos Corp (GKOS) stock has reached an all-time high of $184.45, reflecting a 100.01% increase over the past year and a 41.55% revenue surge in Q2 2026. Despite an InvestingPro analysis suggesting the stock may be overvalued, 11 analysts have revised earnings upwards, indicating …

Glaukos SVP & CFO Alex Thurman sells $3.6m in GKOS stock

Alex R. Thurman, SVP and CFO of Glaukos Corp, sold 20,000 shares of GKOS stock for approximately $3.6 million, while also exercising stock options for 20,000 shares. These transactions were performed under a Rule 10b5-1 trading plan. The sale comes as Glaukos stock trades …

GLAUKOS Corp SEC Filing (Aug 11, 2026)

GLAUKOS Corp (GKOS) filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of 60,000 shares of common stock acquired through a stock option exercise on the same date. The aggregate market value of these shares is $10,784,645.13, and …

Assenagon Asset Management S.A. Has $15.20 Million Stock Position in Glaukos Corporation $GKOS

Assenagon Asset Management S.A. significantly increased its stake in Glaukos Corporation (NYSE:GKOS) by 932.5% in the second quarter, now holding 108,736 shares valued at approximately $15.2 million. Glaukos reported strong Q2 earnings with a 49.6% revenue increase year-over-year and beat analyst EPS expectations, though …

How (GKOS) Movements Inform Risk Allocation Models

This article analyzes Glaukos Corporation (NASDAQ: GKOS) using AI models, identifying strong sentiment across all horizons and suggesting an overweight bias. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. …

Glaukos Corporation (GKOS) Stock Analysis: Target Price Insights And Growth Prospects

Glaukos Corporation (GKOS) is a prominent healthcare company specializing in medical devices for eye disorders, currently priced at $180.02. Despite a high forward P/E ratio of 358.64 and negative profitability metrics, the company shows robust revenue growth of 49.50% and strong analyst sentiment with …

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (GKOS) reported record second-quarter 2026 net sales of $185.6 million, a 50% increase year-over-year, driven by strong adoption of iDose TR and the launch of Epioxa. The company raised its full-year 2026 net sales guidance to $680 million to $700 million and provided …

Is Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?

Dimensional Fund Advisors LP Sells 6,377 Shares of Glaukos Corporation $GKOS

Dimensional Fund Advisors LP has reduced its stake in Glaukos Corporation (NYSE:GKOS) by 3.1%, selling 6,377 shares and retaining 199,084 shares valued at approximately $21.4 million. Despite this, institutional investors collectively own 99.04% of Glaukos's stock, and analysts maintain a "Moderate Buy" rating with …

A Look at Glaukos Corp (GKOS) After 5.3% Gain -- GF Value $147.7

Glaukos Corp (GKOS) recently saw a 5.3% stock gain, closing at $180.02, but GuruFocus assesses it as 21.8% overvalued with a GF Value of $147.78. Despite a strong GF Score™ of 78/100 and high growth potential (9/10), the company faces significant challenges with low …

Glaukos (NYSE: GKOS) insider Alex R. Thurman plans 20,000-share stock sale

Glaukos Corporation insider Alex R. Thurman has filed a Form 144 to sell 20,000 common shares, valued at approximately $3.6 million, stemming from a stock option exercise on August 7, 2026. This proposed sale follows three previous sales by Thurman in the past three …

Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study

Glaukos Corporation has completed patient enrollment in its U.S. pivotal clinical study for the PRESERFLO MicroShunt, a device designed to lower intraocular pressure in adult patients with primary open-angle glaucoma. The study aims to support a potential 510(k) clearance from the FDA, evaluating a …

Insider Selling: Glaukos (NYSE:GKOS) Director Sells $88,005.75 in Stock

Glaukos Corporation Director Leana Wen sold 525 shares of GKOS stock for $88,005.75 on July 31st, reducing her stake by 2.43%. Despite the insider sale, Glaukos shares rose to $170.90, nearing their 52-week high, following a strong quarterly earnings report that exceeded analyst expectations. …

Glaukos (GKOS) Is Up 12.9% After Raising 2026 Sales Guidance and Advancing PRESERFLO Trial

In late July 2026, Glaukos Corporation reported record second-quarter results, with net sales rising to US$185.61 million and a narrower quarterly loss, and raised its 2026 net sales guidance to US$680 million–US$700 million from US$620 million–US$635 million. Alongside the guidance increase, Glaukos completed enrollment …

Glaukos publishes investor presentation highlighting interventional glaucoma, keratoconus pipeline programs

Glaukos presented its investor strategy focusing on interventional glaucoma to reduce reliance on topical drops, citing high non-compliance rates. Key products include iDose TR, a long-duration travoprost implant, and Epioxa, an FDA-cleared epithelium-on cross-linking therapy for keratoconus. The presentation highlighted clinical metrics for iDose …

Glaukos (NYSE: GKOS) insider plans sale of 525 vested shares

An insider at Glaukos Corporation (NYSE: GKOS), Leana Wen, plans to sell 525 vested shares of common stock with an aggregate market value of $88,005.75 around July 31, 2026. These shares are compensation from restricted stock that vested on May 30, 2025. Wen previously …

Glaukos (GKOS) Posted Record Sales And Raised Guidance, Is The Stock Overvalued?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Glaukos (GKOS) just reported record second quarter sales and raised its 2026 net sales guidance to a range of $680 million to $700 …

Glaukos (GKOS) Could Be 2% Overvalued After Its 2026 Sales Guidance Lift

Glaukos Corporation Stock 12‑Month Price Target Raised to $193.62, Implies 20% Upside

Glaukos Corporation (GKOS) has received a raised 12-month average price target of $193.62 from 13 analysts, up from $163.85. This new target implies a potential upside of approximately 20% from its July 29 closing price. The consensus rating for GKOS remains a "Buy" among …

Stifel raises Glaukos stock price target to $190 on revenue outlook

Stifel raised its price target on Glaukos Corporation (NYSE:GKOS) to $190 from $175, maintaining a Buy rating, based on positive surveys for iDose and Epioxa and a strong revenue outlook, projecting $1.0 billion or more in 2027. This follows Glaukos exceeding Q2 2026 earnings …

Glaukos Corp stock hits 52-week high at 161.67 USD

Glaukos Corp (GKOS) stock recently reached a 52-week high of $161.67, with a year-to-date return of 34% and a 70.14% increase over the past year. Despite this strong performance, InvestingPro analysis indicates the stock may be overvalued relative to its Fair Value. The company …

Needham raises Glaukos stock price target to $201 on guidance boost

Needham has increased its price target for Glaukos Corporation (NYSE:GKOS) to $201 from $150, maintaining a Buy rating, following the company's strong Q2 2026 revenue performance. Glaukos exceeded consensus estimates, driven by iDose and Epioxa, leading management to raise its 2026 revenue guidance by …

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos Corporation GKOS reported a second-quarter 2026 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents by 50%. The figure also improved from the year-ago quarter's adjusted loss of 24 cents per share. The …

Glaukos Corp (GKOS) (Q2 2026) Earnings Call Highlights: Record Revenue Surge and Raised ...

This article first appeared on GuruFocus. Revenue: Record second quarter consolidated net sales of $185.6 million, up 50% on a reported basis and 49% on a constant currency basis versus the year-ago quarter. US Glaucoma Franchise Revenue: Record second quarter net sales of $118.5 …

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say

Glaukos (GKOS) reported $185.61 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 49.5%. EPS of -$0.14 for the same period compares to -$0.24 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $149.57 million, …

Earnings Flash (GKOS) Glaukos Corporation Posts Q2 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.21

Glaukos Corporation (GKOS) reported a Q2 adjusted loss of $0.14 per share, which is better than FactSet's estimated loss of $0.21 per share. The company also announced strong Q2 revenue of $185.6 million, significantly exceeding FactSet's estimate of $150.9 million, and expects 2026 net …

GLAUKOS Corp Q2 2026: Revenue $185.6M, EPS $(0.31) — 10-Q Summary

GLAUKOS Corp reported its second-quarter 2026 results, showing a significant increase in revenue to $185.6M, up 50% year-over-year from $124.1M. Although the company still posted a net loss of $18.4M, the diluted net loss per share improved to $(0.31) from $(0.34) in the prior-year …

Glaukos Corporation (GKOS) Stock Rises on Q2 2026 Earnings

Glaukos Corporation (GKOS) reported Q2 2026 revenue of $185.6 million, an increase of 49.5% year-over-year, surpassing Wall Street expectations. Despite strong revenue growth, the company recorded an operating loss of $17.3 million and a net loss of $18.4 million, or -$0.31 per diluted share. …

Glaukos Announces Second Quarter 2026 Financial Results

ALISO VIEJO, Calif., July 29, 2026--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key …

Glaukos Rises as Investors Weigh Clinical Progress Ahead of Earnings